Bristol Myers Squibb Company (BMY) Slipped due to Lowered EPS Guidance

Cullen Capital Management, LLC, operating under the name Schafer Cullen Capital Management, Inc. (SCCM), has released its “SCCM Value Equity Strategy” third-quarter investor letter. A copy of the letter can be downloaded here. The US equity market continued the rally in the third quarter, with the S&P 500 returning 8.1% and the Russell 1000 Value surging 5.3%. The value equity strategy returned 6.9% (gross of fees) and 6.8% (net of fees) in the quarter, while the Russell 1000 Value and S&P 500 returned 5.3% and 8.1%, respectively, during the same period. The strategy returned 13.0% (gross), YTD, compared to the Russell 1000 Value’s +11.7% return and the S&P 500’s +14.8% return. In addition, you can check the fund’s top 5 holdings to determine its best picks for 2025.

In its third-quarter 2025 investor letter, SCCM Value Equity Strategy highlighted stocks such as Bristol-Myers Squibb Company (NYSE:BMY). Headquartered in Princeton, New Jersey, Bristol-Myers Squibb Company (NYSE:BMY) manufactures, distributes, and sells biopharmaceutical products. On November 19, 2025, Bristol-Myers Squibb Company (NYSE:BMY) stock closed at $45.79 per share. One-month return of Bristol-Myers Squibb Company (NYSE:BMY) was 4.47%, and its shares lost 21.36% of their value over the last 52 weeks. Bristol-Myers Squibb Company (NYSE:BMY) has a market capitalization of $93.217 billion.

SCCM Value Equity Strategy stated the following regarding Bristol-Myers Squibb Company (NYSE:BMY) in its third quarter 2025 investor letter:

“Our stock selection within the Health Care sector detracted from relative performance. Bristol-Myers Squibb Company (NYSE:BMY) (-1.3%) reported results that beat expectations across both its Growth and Legacy portfolios but lowered EPS guidance due to one-time R&D charges and persistent loss-of-exclusivity pressures. Management is focused on stabilizing near-term performance through portfolio realignment, cost discipline, and pipeline advancement. Growth products such as Opdivo, Reblozyl, and Camzyos continue to gain traction, and an expanding late-stage pipeline in oncology and immunology supports a path to re-accelerating earnings as major patent expiries subside later in the decade.”

In another article, we covered Bristol-Myers Squibb Company (NYSE:BMY) and shared the list of best passive income stocks to buy. In addition, please check out our hedge fund investor letters Q3 2025 page for more investor letters from hedge funds and other leading investors.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None. This article is originally published at Insider Monkey.